Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are Candidates for Surgery: Design and Rationale of the REPAIR MR Trial
Journal of the American Heart Association · 21.02.2023 · 12 (4)
DOI: 10.1161/jaha.122.027504 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 21.02.2023. Verfasst von Patrick M McCarthy und 15 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern Medicine Chicago IL. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Heart Valve Prosthesis Implantation. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background The current standard of care for the treatment of patients with primary mitral regurgitation (MR) is surgical mitral valve repair. Transcatheter edge‐to‐edge repair with the MitraClip device provides a less invasive treatment option for patients with both primary and secondary MR. Worldwide, >150 000 patients have been treated with the MitraClip device. However, in the United States, MitraClip is approved for use only in primary patients with MR who are at high or prohibitive risk for mitral valve surgery. The REPAIR MR (Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are Candidates for Surgery) trial is designed to compare early and late outcomes associated with transcatheter edge‐to‐edge repair with the MitraClip and surgical repair of primary MR in older or moderate surgical risk patients. Methods and Results The REPAIR MR trial is a prospective, randomized, parallel‐controlled, open‐label multicenter, noninferiority trial for the treatment of severe primary MR (verified by an independent echocardiographic core laboratory). Patients with severe MR and indications for surgery because of symptoms (New York Heart Association class II–IV), or without symptoms with left ventricular ejection fraction ≤60%, pulmonary artery systolic pressure >50 mm Hg, or left ventricular end‐systolic diameter ≥40 mm are eligible for the trial provided they meet the moderate surgical risk criteria as follows: (1) ≥75 years of age, or (2) if
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Northwestern Medicine Chicago IL.
- Intermountain Healthcare Murray UT.
- Montreal Heart Institute Montreal QC Canada.
- University of Michigan Hospital Ann Arbor MI.
- St. Vincent's Hospital Indianapolis IN.
- New York University Medical Center New York NY.
ORCID-Profile: Patrick M McCarthy, Anita W Asgar, James D Thomas, Federico M Asch, Saibal Kar
Zitieren
APA
McCarthy, P. M., Whisenant, B., Asgar, A. W., Ailawadi, G., Hermiller, J., Williams, M., Morse, A., Rinaldi, M., Grayburn, P., Thomas, J. D., Martin, R., Asch, F. M., Shu, Y., Sundareswaran, K., Moat, N., & Kar, S. (2023). Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are Candidates for Surgery: Design and Rationale of the REPAIR MR Trial. Journal of the American Heart Association, 12(4). https://doi.org/10.1161/jaha.122.027504
Vancouver
McCarthy PM, Whisenant B, Asgar AW, Ailawadi G, Hermiller J, Williams M, et al. Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are Candidates for Surgery: Design and Rationale of the REPAIR MR Trial. Journal of the American Heart Association. 2023;12(4). doi:10.1161/jaha.122.027504
BibTeX
@article{McCarthy2023,
author = {McCarthy, Patrick M and Whisenant, Brian and Asgar, Anita W and Ailawadi, Gorav and Hermiller, James and Williams, Mathew and Morse, Andrew and Rinaldi, Michael and Grayburn, Paul and Thomas, James D and Martin, Randolph and Asch, Federico M and Shu, Yu and Sundareswaran, Kartik and Moat, Neil and Kar, Saibal},
title = {Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are Candidates for Surgery: Design and Rationale of the REPAIR MR Trial},
journal = {Journal of the American Heart Association},
year = {2023},
volume = {12},
number = {4},
doi = {10.1161/jaha.122.027504}
}
EUVIMED